XML 54 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Restructuring
12 Months Ended
Dec. 31, 2012
Restructuring
16. Restructuring
 
 In December 2012 the Company announced the closure of its tissue engineering facility in Abano Terme, Italy due to the inability to meet strict regulatory standards, effective January 1, 2013, established by the EMA for Advanced Therapy Medicinal Products. The restructuring plan primarily involves a workforce reduction as well as associated asset abandonments. We recorded restructuring and impairment charges in the fourth quarter of approximately $2.5 million. Of the total restructuring and impairment charges related to our tissue engineering operation, approximately $1.2 million related to the noncash termination and related impairment of an IPR&D project, $0.3 million related to the noncash disposal of property and equipment, and $0.1 million related to the disposal of inventory. The remaining $0.9 million relates to cash payments anticipated to occur in 2013, primarily for employee termination costs. We expect to substantially complete the restructuring plan by the end of the first six months of 2013.